Michael Woody represents biopharmaceutical and medical device clients on legislative issues before the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP), Finance Committee, and the House Energy and Commerce Committee and regulatory issues before the Food and Drug Administration (FDA). He provides policy development, legislative strategy and advocacy services to biotechnology, pharmaceutical and biodefense clients.
Andrew Hawkins has over ten years of experience in government, political, and policy organizations, and represents pharmaceutical and biodefense clients before the U.S. Congress including the House Energy and Commerce Committee and Ways and Means Committee. He provides expertise regarding political programs, legislative strategy, and policy development.
Kelly Childress Lange represents pharmaceutical and biotechnology clients on legislative issues before the U.S. Congress and on regulatory matters before the Food and Drug Administration (FDA) and other agencies. She focuses her practice on biodefense and pandemic issues and provides regulatory counsel to clients from early product development to FDA approval and through the Federal government procurement process.
David Mohler has 20 years of experience helping companies and trade associations manage issues involving federal drug programs, FDA regulation, intellectual property, and Medicare and Medicaid. In addition, David has developed expertise in designing strategic coalitions, and managing large public affairs campaigns.